Suppr超能文献

比较新型三氮唑类药物与现有抗真菌药物对引起足癣的皮肤癣菌的体外抗真菌活性。

Comparison of in vitro antifungal activity of novel triazoles with available antifungal agents against dermatophyte species caused tinea pedis.

机构信息

Department of Mycology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.

Microbiology Laboratory, Department of Biology, Faculty of Science, Razi University, Kermanshah, Iran.

出版信息

J Mycol Med. 2020 Jun;30(2):100935. doi: 10.1016/j.mycmed.2020.100935. Epub 2020 Jan 30.

Abstract

OBJECTIVE

Dermatophytes are a group of keratinophilic fungi that invade and infect the keratinized tissues and cause dermatophytosis. We investigated effectiveness of novel triazole (luliconazole and lanaconazole) in comparison with available antifungal agents against dermatophyte species isolated from patients with tinea pedis.

MATERIAL AND METHODS

A total of 60 dermatophytes species were isolated from the patients with tinea pedis. Identification of species was done by DNA sequencing of the ITS1-5.8S rDNA-ITS2 rDNA region. In vitro antifungal susceptibility testing with luliconazole and lanaconazole and available antifungal agent was done in accordance with the Clinical and Laboratory Standards Institute, M38-A2 document.

RESULTS

In all investigated isolates, luliconazole had the lowest minimum inhibitory concentration (MIC) (MIC range=0.0005-0.004μg/mL), while fluconazole (MIC range=0.4-64μg/mL) had the highest MICs. Geometric mean MIC was the lowest for luliconazole (0.0008μg/mL), followed by lanoconazole (0.003μg/mL), terbinafine (0.019μg/mL), itraconazole (0.085 μg/mL), ketoconazole (0.089μg/mL), econazole (0.097μg/mL), griseofulvin (0.351 μg/mL), voriconazole (0.583μg/mL) and fluconazole (11.58μg/mL).

CONCLUSION

The novel triazoles showed potent activity against dermatophytes and promising candidates for the treatment of tinea pedis caused by Trichophyton and Epidermophyton species. However, further studies are warranted to determine the clinical implications of these investigations.

摘要

目的

皮肤癣菌是一组嗜角质真菌,它们会入侵并感染角蛋白组织,导致皮肤癣病。我们研究了新型三唑类药物(卢立康唑和拉那康唑)与现有抗真菌药物相比,对从足癣患者中分离出的皮肤癣菌的疗效。

材料与方法

从足癣患者中分离出 60 种皮肤癣菌。通过 ITS1-5.8S rDNA-ITS2 rDNA 区域的 DNA 测序来进行种属鉴定。根据临床和实验室标准协会(CLSI)M38-A2 文件进行卢立康唑和拉那康唑以及现有抗真菌药物的体外抗真菌药敏试验。

结果

在所研究的所有分离株中,卢立康唑的最低抑菌浓度(MIC)最低(MIC 范围=0.0005-0.004μg/mL),而氟康唑(MIC 范围=0.4-64μg/mL)的 MIC 最高。卢立康唑的几何平均 MIC 最低(0.0008μg/mL),其次是拉那康唑(0.003μg/mL)、特比萘芬(0.019μg/mL)、伊曲康唑(0.085μg/mL)、酮康唑(0.089μg/mL)、益康唑(0.097μg/mL)、灰黄霉素(0.351μg/mL)、伏立康唑(0.583μg/mL)和氟康唑(11.58μg/mL)。

结论

新型三唑类药物对皮肤癣菌具有较强的活性,是治疗由须癣毛癣菌和表皮癣菌引起的足癣的有希望的候选药物。然而,需要进一步的研究来确定这些研究的临床意义。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验